MyFinsight
Home
Blog
About
Decrease in cash and cash
equivalents
-$6,043K
(62.26%↑ Y/Y)
Share-based compensation
$1,317K
(-69.68%↓ Y/Y)
Prepaid expenses and
other current assets
-$681K
(-539.35%↓ Y/Y)
Accrued expenses and
other liabilities
$577K
(6.85%↑ Y/Y)
Foreign currency
transaction gain/(loss)
-$361K
(95.54%↑ Y/Y)
Amortization of operating
lease right-of-use...
$134K
(-48.85%↓ Y/Y)
Amortization of intangible
assets
$127K
(-43.30%↓ Y/Y)
Depreciation
$38K
(-53.66%↓ Y/Y)
Non-cash interest
expense
$7K
(-96.37%↓ Y/Y)
Operating lease
liabilities
$1K
(100.28%↑ Y/Y)
Net cash used in
operating activities
-$6,043K
(62.18%↑ Y/Y)
Canceled cashflow
$3,243K
Net loss
-$7,005K
(74.53%↑ Y/Y)
Accounts payable
-$2,137K
(-34.49%↓ Y/Y)
Research and development
incentives receivable
$119K
(157.21%↑ Y/Y)
Non-cash interest income
$19K
Change in fair value of
warrants
-$6K
(98.10%↑ Y/Y)
Back
Back
Cash Flow
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)
source: myfinsight.com